Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio, Inc. develops buntanetap, an investigational oral therapy for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease. News about ANVS commonly centers on clinical development of buntanetap, peer-reviewed publications, biomarker data, safety findings, and scientific presentations related to the company’s multi-protein approach to neurodegeneration.
Recurring updates also cover intellectual-property protection for buntanetap and related compounds, collaborations that add digital biomarker technology to Parkinson’s disease research, corporate financing, annual financial results, and other public-company developments tied to funding, governance, and clinical-regulatory disclosure.
Annovis Bio Inc. (NYSE American: ANVS) announced that its Founder and CEO, Maria Maccecchini, Ph.D., will receive the 2020 Smart Business Dealmaker Award at the Smart Business Dealmakers Conference on October 22. Dr. Maccecchini expressed gratitude for the recognition and highlighted the team's efforts that contributed to the company’s successful IPO earlier this year. Annovis Bio is focused on treating neurodegenerative diseases, including Alzheimer's and Parkinson's, and is currently conducting Phase 2a studies on its treatments. The award ceremony runs from 12:30 PM to 1:00 PM ET.
On October 20, 2020, Annovis Bio (NYSE American: ANVS) announced participation by CEO Maria Maccecchini, Ph.D., in the Financial Times' Outstanding Director Exchange (ODX) Roundtable, discussing the evolving relationship between pharma and biotech. She will also join the Angel Venture Fair Women’s Founders and Funders panel. With extensive experience since 1992, Dr. Maccecchini aims to share insights beneficial to directors and aspiring women entrepreneurs. Annovis specializes in treatments for Alzheimer’s and Parkinson’s diseases, with ongoing clinical studies aimed at improving cognitive and motor functions.
On October 15, 2020, Annovis Bio Inc. (ANVS) reported significant advancements in its business operations for Q3 2020. The company announced the initiation of a Phase 2a clinical study for its lead compound, ANVS401, targeting Alzheimer’s and Parkinson’s diseases, with preliminary data expected in early 2021. Annovis Bio also restarted a previously halted Alzheimer's study, completed a chronic toxicology study with favorable safety results, and published three scientific papers corroborating its findings. Additionally, the company secured two patents and filed five more related to treatments for neurodegenerative diseases.
On October 12, 2020, Annovis Bio (NYSE American: ANVS) announced that its CEO, Maria Maccecchini, will present at the 2020 BIO Investor Forum, taking place October 13-15, 2020, in a digital format. The presentation will be available on demand for registered attendees. Annovis Bio focuses on developing treatments for Alzheimer’s disease (AD), Parkinson’s disease (PD), and Alzheimer’s in Down Syndrome (AD-DS), targeting neurotoxic proteins to enhance nerve cell function. For further information, visit www.annovisbio.com.
On September 3, 2020, Annovis Bio Inc. (NYSE American: ANVS) announced a televised interview with CEO Maria Maccecchini, airing on The RedChip Money Report on September 6 at 6 p.m. local time. The interview will discuss the Company's innovative approach to treating neurodegenerative diseases, including ongoing Phase 2a studies in Alzheimer’s and Parkinson’s diseases. Additionally, viewers can catch the program in the U.S. on the Action Channel. Annovis focuses on multi-target solutions for neurodegeneration, aiming to improve conditions like memory loss associated with Alzheimer's.
On September 1, 2020, Annovis Bio Inc. (ANVS) announced the dosing of the first three patients in its Phase 2a clinical trial for Alzheimer’s disease (AD) and Parkinson’s disease (PD). The trial, which has IRB approval, will enroll a total of 28 patients over four weeks, focusing on the drug ANVS401's ability to reverse toxic nerve cell death. Initial data is expected in early 2021, followed by a larger dose-response trial. This is a significant milestone for the company, which aims to offer a novel treatment for these neurodegenerative diseases.
Annovis Bio Inc. (NYSE American:ANVS) announced its participation in the LD 500 investor conference on September 1, 2020, at 9:20 AM EDT. CEO Maria Maccecchini will present the company’s innovative approach to treating Alzheimer’s, Parkinson’s, and other neurodegenerative diseases. The company is currently conducting two Phase 2 trials focused on these conditions. The LD 500, running from September 1-4, will be virtual, making it accessible to all interested parties. For more information, visit annovisbio.com.
Annovis Bio Inc. (NYSE American: ANVS) has resumed patient recruitment for its suspended Phase 2a clinical trial targeting Alzheimer’s disease (AD) and initiated a new Phase 2a trial for both AD and Parkinson’s disease (PD). The first trial involves 24 patients and is in collaboration with major institutions. Initial data is expected in early 2021. The second trial will also enroll patients across 15 US sites, with results anticipated in summer 2021. The company plans to report final data from long-term toxicology studies by fall 2020 to confirm the safety of its lead compound, ANVS401.
On July 23, 2020, Annovis Bio (NYSE American: ANVS) announced that CEO Maria Maccecchini will appear on Executive Leaders Radio on July 26, 2020. The show focuses on interviews with prominent CEOs, particularly within life sciences, discussing professional success and personal stories. Dr. Maccecchini expressed her enthusiasm for sharing the Annovis story and her personal commitment to neurodegeneration solutions. Annovis Bio, based in Berwyn, PA, is focused on developing drugs for Alzheimer’s and Parkinson’s diseases, with ongoing Phase 2a studies targeting these conditions.
Annovis Bio (NYSE American: ANVS) announces that CEO Maria Maccecchini, Ph.D., will present at the University of Pennsylvania on July 20, 2020. Her talk, titled “Rethinking Parkinson’s Disease”, addresses a novel treatment approach for Parkinson's disease at the Parkinson’s Disease and Movement Disorders Center, recognized as a global Center of Excellence.
Maccecchini will discuss the toxic cascade caused by neurotoxic proteins in neurodegenerative diseases, presenting data from clinical trials using ANVS401, Annovis Bio's lead compound.